Top Markets
#1 Nesa Nesa +801.14%
#2 Cortex Cortex +68.31%
#3 Wrapped Aave Ethereum USDT Wrapped Aave Ethereum USDT +66.37%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.38%
#5 Pons Pons +24.75%
#6 QuantixAI QuantixAI +23.71%
#7 EXOD EXOD +22.78%
#8 Instadapp Instadapp +18.46%
#9 Movement Movement +12.30%
#10 SkyAI SkyAI +11.87%
Coin of the day
Nesa Nesa
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Surrozen, Inc. Surrozen, Inc.

Surrozen, Inc.

SRZN
Rang in Aktien #19455
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates... Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Aktienkurs
$21.57
Zuletzt synchronisiert: 2026-07-31
Marktkapitalisierung
$161.29M
Veränderung (1 Tag)
3.55%
Veränderung (1 Jahr)
94.32%
Land
US
Handel Surrozen, Inc. (SRZN)

Kategorie

Healthcare
EPS für Surrozen, Inc. (SRZN)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Surrozen, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Surrozen, Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH